TABLE 1.
Patient Characteristics
| Addition of Wl12 (ΜG) | Patient | Sex | Age (y) | ECOG score | Tumor type | PD-L1 expression* | Clinical stage | Tumor size (cm) | Therapy regimen |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 1 | M | 47 | 1 | LUSC | 8% | cT4N2M1a IVa | 7.2 × 6.1 | Nab-paclitaxel + carboplatin + pembrolizumab |
| 0 | 2 | M | 72 | 0 | LUSC | 35% | cT2N3M0 IIIb | 4 × 3.4 | Paclitaxel + cisplatin |
| 5 | 3 | M | 68 | 0 | LUSC | 8% | cT4N1M1a IVa | 5.8 × 4.7 | Nab-paclitaxel + carboplatin + pembrolizumab |
| 60 | 4 | M | 68 | 1 | LUAC | 25% | cT4N1M0 IIIa | 5.1 × 4.0 | Nab-paclitaxel + carboplatin |
| 120 | 5 | M | 80 | 2 | LUAC | 40% | cT4N3M1c IVb | 5.7 × 3.9 | toripalimab |
| 6 | M | 58 | 0 | LUAC | 30% | cT2aN2M1c IVb | 3.1 × 2.3 | Pemetrexed + carboplatin + pembrolizumab | |
| 7 | M | 63 | 1 | LUSC | 25% | cT2bN2M1b IVa | 4.2 × 4.1 | pembrolizumab | |
| 8 | M | 53 | 1 | LUAC | 35% | cT2bN2M1b IVa | 3.1 × 1.9 | Pemetrexed + carboplatin + sintilimab | |
| 9 | F | 80 | 2 | LUAC | 80% | cT3N3M1c IVb | 5.9 × 5.3 | Pembrolizumab |
ECOG = Eastern Cooperative Oncology Group; LUSC = lung squamous cell carcinoma; LUAC = lung adenocarcinoma.